Occult primary.
暂无分享,去创建一个
D. Ettinger | A. Rashid | L. Kvols | L. Saltz | L. Shulman | R. Lenzi | C. Jacobs | M. Agulnik | M. Cristea | K. Eaton | P. Fidias | J. Gockerman | C. Handorf | J. Zager | W. Zhen | N. Khushalani | O. Hameed | M. Javle | N. Lewis | Elizabeth I Harris
[1] M. Erlander,et al. Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: A prospective, phase II trial. , 2010 .
[2] Denise,et al. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. , 2010, The oncologist.
[3] W. E. Jordan,et al. Cancer of unknown primary site. , 2010, Seminars in oncology.
[4] R. Aharonov,et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin , 2010, Modern Pathology.
[5] F. Monzon,et al. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. , 2010, Archives of pathology & laboratory medicine.
[6] F. Monzon,et al. Diagnosis of uncertain primary tumors with the Pathwork® tissue-of-origin test , 2010, Expert review of molecular diagnostics.
[7] A. Gothelf,et al. Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study , 2010, Acta oncologica.
[8] J. Hainsworth,et al. Paclitaxel/Carboplatin/Etoposide Versus Gemcitabine/Irinotecan in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site: A Randomized, Phase III Sarah Cannon Oncology Research Consortium Trial , 2010, Cancer journal.
[9] J. Hainsworth,et al. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. , 2009, The oncologist.
[10] L. Truong,et al. Undifferentiated tumor: true identity by immunohistochemistry. , 2009, Archives of pathology & laboratory medicine.
[11] R. Salunga,et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. , 2009, Archives of pathology & laboratory medicine.
[12] G. Calais,et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. , 2009, Journal of the National Cancer Institute.
[13] R. Coleman,et al. NCCN task force: clinical utility of PET in a variety of tumor types. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[14] F. Monzon,et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. French,et al. Carcinomas of the Upper Aerodigestive Tract With Rearrangement of the Nuclear Protein of the Testis (NUT) Gene (NUT Midline Carcinomas) , 2009, Advances in anatomic pathology.
[16] M. Erlander,et al. Molecular classification of unknown primary cancer. , 2009, Seminars in oncology.
[17] J. Hainsworth,et al. Neuroendocrine carcinoma of unknown primary site. , 2009, Seminars in oncology.
[18] S. Culine. Prognostic factors in unknown primary cancer. , 2009, Seminars in oncology.
[19] K. Oien,et al. Pathologic evaluation of unknown primary cancer. , 2009, Seminars in oncology.
[20] J. Hainsworth,et al. Treatment for patients with unknown primary cancer and favorable prognostic factors. , 2009, Seminars in oncology.
[21] G. Varadhachary,et al. Overview of patient management and future directions in unknown primary carcinoma. , 2009, Seminars in oncology.
[22] P. Schőffski,et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial , 2008, British Journal of Cancer.
[23] Kenneth R Hess,et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Aharonov,et al. MicroRNAs accurately identify cancer tissue origin , 2008, Nature Biotechnology.
[25] M. Wick. Immunohistochemical approaches to the diagnosis of undifferentiated malignant tumors. , 2008, Annals of diagnostic pathology.
[26] T. Economopoulos,et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study , 2008, Acta oncologica.
[27] M. Morrow,et al. MRI and breast cancer: role in detection, diagnosis, and staging. , 2007, Oncology.
[28] K. Griffith,et al. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site , 2007, Cancer.
[29] N. Saijo,et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 , 2007, British Journal of Cancer.
[30] B. Skogseid,et al. Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors , 2007, Clinical Cancer Research.
[31] J. Hainsworth,et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Mackey,et al. The role of 2‐deoxy‐2‐[F‐18]fluoro‐D‐glucose positron emission tomography in disseminated carcinoma of unknown primary site , 2007, Cancer.
[33] V. Ambrosini,et al. 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin , 2006, La radiologia medica.
[34] J. Hainsworth,et al. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] David C. Atkins,et al. A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. , 2006, The Journal of molecular diagnostics : JMD.
[36] K. Fizazi. Carcinoma of an Unknown Primary Site , 2006 .
[37] M. Mancini,et al. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[38] Jeffrey W. Clark,et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Carles,et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] E. Morris,et al. Utility of Breast Magnetic Resonance Imaging in Patients With Occult Primary Breast Cancer , 2005, Annals of Surgical Oncology.
[41] N. Pavlidis,et al. Cancer of unknown primary (CUP). , 2005, Critical reviews in oncology/hematology.
[42] Mack Roach,et al. Advances in Radiation Therapy: Conventional to 3D, to IMRT, to 4D, and Beyond , 2005, CA: a cancer journal for clinicians.
[43] C. Nanni,et al. Role of 18F-FDG PET–CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[44] Howard,et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. , 2004, The oncologist.
[45] C. Antonescu,et al. Midline carcinoma of children and young adults with NUT rearrangement. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] H. Demir,et al. The role of nuclear medicine in the diagnosis of cancer of unknown origin. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[47] R. Lenzi,et al. Diagnostic strategies for unknown primary cancer , 2004, Cancer.
[48] J. Jassem,et al. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. , 2004, Cancer treatment reviews.
[49] S. Culine,et al. Gemcitabine and docetaxel as front‐line chemotherapy in patients with carcinoma of an unknown primary site , 2004, Cancer.
[50] A. Hartmann,et al. Cancer of unknown primary: clinicopathologic correlations , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[51] P. Petrow,et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] J. Hainsworth,et al. Diagnostic and therapeutic management of cancer of an unknown primary. , 2003, European journal of cancer.
[53] S. Culine,et al. Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002) , 2003, British Journal of Cancer.
[54] R. Delgado-Bolton,et al. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[55] N. Pavlidis. Cancer of unknown primary: biological and clinical characteristics. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] H. Hillen,et al. The unknown biology of the unknown primary tumour: a literature review. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[57] P. Chu,et al. Keratin expression in human tissues and neoplasms , 2002, Histopathology.
[58] J. Hainsworth,et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] M Dietel,et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. , 2001, American journal of clinical pathology.
[60] M. Fjällskog,et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors , 2001, Cancer.
[61] J. Hainsworth,et al. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. , 2001, Cancer journal.
[62] J. Hainsworth,et al. Carcinoma of unknown primary site , 2000, Cancer.
[63] H. Hillen. Unknown primary tumours , 2000, Postgraduate medical journal.
[64] N. Pavlidis,et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] P. Chu,et al. Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases , 2000, Modern Pathology.
[66] J. Olson,et al. Magnetic Resonance Imaging Facilitates Breast Conservation for Occult Breast Cancer , 2000, Annals of Surgical Oncology.
[67] J. Hainsworth,et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] K R Hess,et al. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[69] S. Edge,et al. Breast MRI in the Evaluation of Patients with Occult Primary Breast Carcinoma , 1999, The breast journal.
[70] N. Pavlidis,et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. , 1998, Anticancer research.
[71] J. Roodenburg,et al. Detection of unknown occult primary tumors using positron emission tomography , 1998, Cancer.
[72] J. Hainsworth,et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] K. Hess,et al. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] K. Hess,et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] B. Jeremic,et al. Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. , 1993, Journal of chemotherapy.
[76] J. Hainsworth,et al. Treatment of patients with cancer of an unknown primary site. , 1993, The New England journal of medicine.
[77] F. Muggia,et al. Management of peritoneal carcinomatosis of unknown primary tumor site. , 1993, Seminars in oncology.
[78] J. Hainsworth,et al. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] J. Hainsworth,et al. Tumors of unknown origin , 1992, CA: a cancer journal for clinicians.
[80] L. Kvols,et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms , 1991, Cancer.
[81] J. Hainsworth,et al. Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. , 1989, Annals of internal medicine.
[82] Y. Bécouarn,et al. Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary. , 1989, European journal of cancer & clinical oncology.
[83] M. Wick,et al. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. , 1989, Human pathology.
[84] J. Hainsworth,et al. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. , 1988, Annals of internal medicine.
[85] M. Tattersall,et al. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. , 1987, European journal of cancer & clinical oncology.
[86] T. Saclarides,et al. Hormone receptor studies in axillary metastases from occult breast cancers , 1987, Cancer.
[87] T. Keane,et al. Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases , 1987, Cancer.
[88] T. Therneau,et al. Lack of Value for Cisplatin Added to Mitomycin‐Doxorubicin Combination Chemotherapy for Carcinoma of Unknown Primary Site A Randomized Trial , 1987, American journal of clinical oncology.
[89] M. Burgess,et al. Prognostic factors in metastatic carcinoma of unknown primary. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] R. Goldberg,et al. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] M. Tattersall,et al. Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. , 1980, The New England journal of medicine.
[92] Cx Utrecht. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis , 2009 .
[93] J. Pollack,et al. Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. , 2008, The Journal of molecular diagnostics : JMD.
[94] J. Debatin,et al. Unknown primary tumors: detection with dual-modality PET/CT--initial experience. , 2005, Radiology.
[95] David W Townsend,et al. PET/CT today and tomorrow. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[96] A. Griffioen,et al. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. , 2004, Anticancer research.
[97] V. Anand,et al. Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. , 1995, Cancer investigation.
[98] J. Verweij,et al. Carcinoma of unknown primary: identification of a treatable subset? , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.
[99] G. Falkson,et al. Treatment and prognosis of metastatic carcinoma of unknown primary: analysis of 100 patients. , 1989, Medical and pediatric oncology.
[100] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.